ascopubs.org

LEAP-014: An open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal squamous cell carcinoma.

INTEGRATE IIb: A randomized phase III open label study of regorafenib + nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC). This is an ASCO Meeting Abstract ...
ascopubs.org

Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.

EX103: A newly designed CD20×CD3 molecule in heavily pre-treated patients with B-cell non-Hodgkin lymphoma from a phase I/II trial. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...

SPEC Releases The SPEC CPU 2026 Benchmark Suites To Address The Latest Advances In CPU, Memory, And Compiler Technology

SPEC Releases The SPEC CPU 2026 Benchmark Suites To Address The Latest Advances In CPU, Memory, And Compiler Technology. Updated suites reflect a multi-year collaboration between competing organizatio ...
PCMag UK

The Best Web Hosting Services for 2026

Selecting the right web host is essential for online success. The best web hosting services we've tested cater to a wide ...